الفهرس 
Title : Impact of Human Papilloma Virus HPV on Immunosenescent CD57+ T-lymphocytes in Cervical Cancer Patients
ContentsOnly 14 pages are availabe for public view
 |  | from | 102 |  |  |
| | | from | 102 | | |
Abstract
Human papilloma virus (HPV) related cervical cancer (CC) remains
a significant cause of mortality, especially in developing nations. Practical,
cheap, and responsive biomarkers are required to diagnose and prevent
large-scale CCs and other cancers associated with HPV. This research aimed
to investigate HPV-Human leukocyte Antigen-G (HLA-G) interaction with
the cervical cancer immune modulation: Hypothesizing HPV-specific HLA
markers might be accurate and costeffective preventive biomarkers. In
addition to assessing the host immune response by immunophenotyping of
CD57 natural killer T-cells. Forty-five DNA and serum samples of the
patients were divided into two groups; twenty-three cases with HPV
infection associated with cervical cancer and twenty-two controls with HPV
infection without cervical cancer. Real-Time Quantitative polymerase chain
reaction (RT-PCR) was used for HLA-G messenger RNA expression.
Immunophenotyping by flow cytometry was carried out using specific
monoclonal antibodies against CD57 expressed on CD8+
T-cells. The results
indicated that 69.6% of the cases showed HLA-G expression compared to
only 22.7% of the controls, and the difference was statistically significant at
p<0.01. Cases have eight times the risk of expression among controls since
odd ratio (OR) =7.8. Also, 65.2% of the cases showed CD57+ expression
compared to 36.4% of the controls, and the difference was marginally
significantly different at p= 0.053. Cases have nearly three times the risk of
expression among controls since OR=3.3. Although the lower limit of the
95% confidence interval is <1, indicating that in the population, this increase
in risk may not be present. HPV-specific HLA-G marker test might be an
accurate and cost-effective preventive biomarker with potential application
for cervical cancer